BACKGROUND: Replication of effective practices requires detailed descriptions of implementation processes, barriers and facilitators, and lessons learned. The experiences of physicians leading the Buprenorphine HIV Evaluation and Support initiative provides valuable information for other HIV providers seeking to integrate medication-assisted treatment services into HIV clinical care. METHODS: Evaluation staff conduced site visits to the 10 funded Buprenorphine HIV Evaluation and Support programs to better understand buprenorphine/naloxone (bup/nx) integration practices; services offered; staffing; provider experiences with and perceptions of bup/nx; perceived barriers, facilitators, and sustainability; and recommendations regarding replication of integrated care program components. Interviews with site principal investigators conducted during the last year of program implementation were transcribed, coded, and analyzed according to both pre-identified and emerging themes. RESULTS: Integrated bup/nx and HIV treatment was successfully introduced to community and hospital-based clinics under the direction of infectious disease, psychiatry, and general internal medicine physicians. All but 1 of the principal investigators interviewed were highly satisfied with integrated HIV and bup/nx treatment, and all anticipated continued provision of the service. Multiple prescribers were necessary to ensure sufficient coverage and a bup/nx coordinator (eg, nurse, counselor) was seen as essential to the provision of quality care. Ongoing challenges included multisubstance use and mental health issues among patients; limited adoption of bup/nx treatment among colleagues; and the necessity of incorporating new procedures, including urine toxicology testing into established practice. CONCLUSIONS: Findings suggest that integrated bup/nx treatment and HIV care is acceptable to providers and feasible in a variety of practice settings.
BACKGROUND: Replication of effective practices requires detailed descriptions of implementation processes, barriers and facilitators, and lessons learned. The experiences of physicians leading the Buprenorphine HIV Evaluation and Support initiative provides valuable information for other HIV providers seeking to integrate medication-assisted treatment services into HIV clinical care. METHODS: Evaluation staff conduced site visits to the 10 funded Buprenorphine HIV Evaluation and Support programs to better understand buprenorphine/naloxone (bup/nx) integration practices; services offered; staffing; provider experiences with and perceptions of bup/nx; perceived barriers, facilitators, and sustainability; and recommendations regarding replication of integrated care program components. Interviews with site principal investigators conducted during the last year of program implementation were transcribed, coded, and analyzed according to both pre-identified and emerging themes. RESULTS: Integrated bup/nx and HIV treatment was successfully introduced to community and hospital-based clinics under the direction of infectious disease, psychiatry, and general internal medicine physicians. All but 1 of the principal investigators interviewed were highly satisfied with integrated HIV and bup/nx treatment, and all anticipated continued provision of the service. Multiple prescribers were necessary to ensure sufficient coverage and a bup/nx coordinator (eg, nurse, counselor) was seen as essential to the provision of quality care. Ongoing challenges included multisubstance use and mental health issues among patients; limited adoption of bup/nx treatment among colleagues; and the necessity of incorporating new procedures, including urine toxicology testing into established practice. CONCLUSIONS: Findings suggest that integrated bup/nx treatment and HIV care is acceptable to providers and feasible in a variety of practice settings.
Authors: Benjamin J Oldfield; Nicolas Muñoz; Mark P McGovern; Melissa Funaro; Merceditas Villanueva; Jeanette M Tetrault; E Jennifer Edelman Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Rupali Kotwal Doshi; Nicholas S Vogenthaler; Sarah Lewis; Allan Rodriguez; Lisa Metsch; Carlos del Rio Journal: AIDS Res Hum Retroviruses Date: 2012-03-02 Impact factor: 2.205
Authors: E Jennifer Edelman; Stephen A Maisto; Nathan B Hansen; Christopher J Cutter; James Dziura; Lynn E Fiellin; Patrick G O'Connor; Roger Bedimo; Cynthia Gibert; Vincent C Marconi; David Rimland; Maria C Rodriguez-Barradas; Michael S Simberkoff; Amy C Justice; Kendall J Bryant; David A Fiellin Journal: Contemp Clin Trials Date: 2016-11-20 Impact factor: 2.226
Authors: Nancy L Sohler; Linda Weiss; James E Egan; Carolina M López; Jamie Favaro; Robert Cordero; Chinazo O Cunningham Journal: J Opioid Manag Date: 2013 Mar-Apr
Authors: Mari-Lynn Drainoni; Caitlin Farrell; Amy Sorensen-Alawad; Joseph N Palmisano; Christine Chaisson; Alexander Y Walley Journal: AIDS Patient Care STDS Date: 2014-01-15 Impact factor: 5.078